U.S. Physical Therapy, Inc. (USPH) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. U.S. Physical Therapy, Inc. operates two reportable segments: Physical Therapy Operations (681 clinics in 42 states) and Industrial Injury Prevention (IIP) Services. The company continues its strategy of acquiring outpatient physical therapy practices and IIP businesses. As of June 30, 2024, the company operated 681 clinics and managed 41 additional practices for third parties.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $167.2 million | $151.5 million | $322.9 million | $300.0 million |
| Operating Income | $19.6 million | $20.1 million | $33.9 million | $37.1 million |
| Net Income (Total) | $11.7 million | $14.9 million | $23.3 million | $26.3 million |
| Net Income Attributable to USPH Shareholders | $7.5 million | $10.9 million | $15.6 million | $18.3 million |
| Diluted EPS (USPH Shareholders) | $0.47 | $0.64 | $0.93 | $1.22 |
| Adjusted EBITDA (Non-GAAP) | $22.1 million | $21.7 million | $38.9 million | $40.1 million |
| Cash and Cash Equivalents | $112.9 million | $160.7 million | $112.9 million | $160.7 million |
| Total Debt (Net) | $145.4 million | $146.7 million | $145.4 million | $146.7 million |
| Available Credit (Revolving) | $175.0 million | $175.0 million | $175.0 million | $175.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 10.4% in Q2 2024 and 7.6% YTD 2024 compared to the prior year periods. Growth was driven by 25 net new clinics added since the comparable prior year period and a 3.0% increase in net rate per patient visit ($105.05 vs. $102.03 in Q2).
- Profitability Pressure: While revenue grew, operating income declined 2.2% in Q2 and 8.4% YTD. Gross margin for Physical Therapy Operations decreased to 20.1% in Q2 (from 21.3% prior year) due to higher operating costs per visit ($84.46 vs. $80.61).
- Non-GAAP Performance: Adjusted EBITDA increased slightly to $22.1 million in Q2 2024. Operating Results (non-GAAP) per share decreased to $0.73 in Q2 2024 from $0.76 in Q2 2023, primarily due to increased shares outstanding from the May 2023 secondary offering.
- Acquisition Activity: Significant investing cash outflows of $48.8 million YTD 2024 were driven by the purchase of business interests ($38.7 million) and non-controlling interests ($6.8 million). Notable acquisitions included a 100% interest in an IIP business in April 2024 and a 50% interest in a nine-clinic practice in March 2024.
- Other Income/Expense: A $4.0 million loss in Q2 2024 related to the change in fair value of contingent earn-out consideration negatively impacted net income, compared to a gain in the prior year period.
Guidance, Outlook, and Risks
- Dividends: The Board declared a quarterly dividend of $0.44 per share, payable September 13, 2024.
- Liquidity: Management believes cash and credit facilities are sufficient to fund operations through at least June 30, 2025. The company maintains a $175 million revolving credit facility with no outstanding balance as of June 30, 2024.
- Regulatory Risks: The company faces potential reimbursement reductions from Medicare (approx. 1.8% reduction in 2024, with a proposed 2.8% reduction for 2025). There is also a risk regarding the Federal Trade Commission's rule on non-competition agreements, which could impact the company's ability to retain staff if the rule becomes effective.
- Contingencies: The company has significant redeemable non-controlling interest (temporary equity) valued at $184.4 million. Revaluations of these interests and contingent earn-out liabilities can cause volatility in earnings.
Investor Verification Checklist
- Reimbursement Rates: Verify the impact of the 1.8% Medicare reduction and the proposed 2025 reduction on future margins, given the company's reliance on third-party payors.
- Cost Per Visit: Monitor the trend in operating costs per visit ($84.46 in Q2 2024) to ensure it does not outpace the net rate per patient visit growth.
- Acquisition Integration: Assess the financial contribution of the 25 net new clinics added in the last 12 months to determine if they are achieving expected profitability.
- Contingent Liabilities: Review the valuation assumptions for the $17.2 million contingent earn-out consideration and the $184.4 million redeemable non-controlling interest, as changes in these valuations directly impact net income and retained earnings.
- Non-Compete Risk: Evaluate the potential operational impact if the FTC's non-competition rule is upheld, specifically regarding the retention of employed therapists.